Health
Intracranial Responses Are Induced With Entrectinib in NTRK+ Tumors – Targeted Oncology
Patients with NTRK fusion–positive solid tumors and baseline CNS metastases demonstrated durable intracranial activity with entrectinib, according to results of a small subpopulation analysis presented at the 2020 ESMO Virtual Congress.
Patients with NTRK fusionpositive solid tumors and baseline CNS metastases demonstrated durable intracranial activity with entrectinib (Rozlytrek), according to results of a small subpopulation analysis presented at the 2020 ESMO Virtual Congress.
In this analysis of patients with NTRK fusion-positive, TRK inhibitor-naïve solid tumors treated with entrectinib, the intracranial objective response rate (ORR) was 50% in all patients with baseline metastases and median intracranial duration of resp…
Continue Reading
